IPCO 2025 @ Johns Hopkins
Event Description
The 26th Conference on Integer Programming and Combinatorial Optimization (IPCO XXVI) will take place on June 11-13, 2025 at the Johns Hopkins University, Baltimore, MD, USA. It will be organized by the Department of Applied Mathematics and Statistics.
The conference will be preceded by a Summer School (June 9-10).
The IPCO conference is under the auspices of the Mathematical Optimization Society and is held every year. The conference is a forum for researchers and practitioners working on various aspects of integer programming and combinatorial optimization. The aim is to present recent developments in theory, computation, and applications in these areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Technical.ly
22-05-2025
- Technical.ly
IPCO 2025 @ Johns Hopkins
Event Description The 26th Conference on Integer Programming and Combinatorial Optimization (IPCO XXVI) will take place on June 11-13, 2025 at the Johns Hopkins University, Baltimore, MD, USA. It will be organized by the Department of Applied Mathematics and Statistics. The conference will be preceded by a Summer School (June 9-10). The IPCO conference is under the auspices of the Mathematical Optimization Society and is held every year. The conference is a forum for researchers and practitioners working on various aspects of integer programming and combinatorial optimization. The aim is to present recent developments in theory, computation, and applications in these areas.
Technical.ly
10-03-2025
- Technical.ly
This stem cell research fund is transforming patient care in Maryland
As executive director of the Maryland Stem Cell Research Fund, Ruchika Nijhara has seen the program's work literally change lives, including the life of a 4-year old patient. This patient suffered from a rare genetic disease that caused his immune cells to not work properly. Between constantly getting pneumonia and coming in to receive interferon gamma shots, he spent a significant amount of his childhood in the hospital. His health was always in question before the Maryland Stem Cell Research Fund (MSCRF) helped alter the course of his life. The MSCRF is an independent program within TEDCO created to promote state-funded human stem cell research and medical treatments through grants to public and private entities in Maryland. It focuses on identifying and fostering cutting-edge research and innovation in the field of regenerative medicine. That's exactly what the young patient needed. He was treated at Johns Hopkins University by Heather Symons and was cured at 10-years old. Now, he's 16 and participating in the STEM field himself. 'This is what the potential of this field is, and our state has always been a leader in life sciences,' Nijhara said. 'We still can't match our funding to what California provides, but whatever we provide has not only shown significant economic impact, but the non-monetary value of our funding is innumerous.' The program was initiated back in 2006, when Sen. Paula Hollinger introduced a bill that aimed to boost funding for embryonic stem cell research. As first proposed, it would've allowed research on human embryos otherwise discarded from fertility clinics, but several critics countered that the proposal was akin to abortion. Even if the bill were to pass, it was unclear if then-Gov. Robert Erlich would sign it. So, Hollinger tweaked the bill's language to provide funding for various kinds of adult stem cell research. While the adult cells are not considered as promising for research purposes, they are less controversial. The approval of this bill led to the establishment of the MSCRF under the Maryland Stem Cell Research Act of 2006. $200+ million to help patients and strengthen the region Part of the goal of the MSCRF is to foster economic development in the region, according to Nijhara. 'We don't want the money to go out [of Maryland],' she said. 'We want to promote economic development in the state. We want to build collaborations and a stronger ecosystem in the state while at the same time making sure that we stay committed to our mission, which is to advance the field to reach patients through curative treatments.' When the fund first launched in 2007, it offered two grants, both primarily targeted toward academic research. In 2017, the MSCRF expanded to include six grant programs, allowing the fund to offer support for clinical trials and help companies secure research sites within the state. With the launch of the Manufacturing Assistance Program in 2023, the MSCRF now offers seven grant programs — Launch, Discovery, Validation, Commercialization, Clinical, Post-doctoral Fellowships and Manufacturing Assistance — all to accelerate research and commercialization of human stem cell-based technologies. These grants help scientists, companies and research organizations accelerate and advance the commercialization of innovative stem cell technologies for a positive impact on human lives. For instance, one MSCRF grant funded research for an innovative technique developed at Johns Hopkins that allows sickle cell anemia patients who don't have the exact genetic makeup in the family to get a transplant, even when they only have half a match. 'Through MSCRF, the Maryland life sciences ecosystem continues to expand, building a community of research and collaboration across the public private sectors,' said Troy LeMaile-Stovall, TEDCO CEO. 'The work that Ruchika and her team do every day leads to a better Maryland, while also promoting hope, enabling cures and building the resources for a better tomorrow.' To date, the MSCRF has allocated $208 million in funding to 600 research projects and 41 different entities within the state such as companies, academic institutions, nonprofits and other organizations. In addition to Johns Hopkins, this includes big players like the Kennedy Krieger Institute, the Lieber Institute of Brain and the entire university system of Maryland. An impressive 75% of the companies the fund has supported since its inception are still in existence. The fund's mission remains to develop new medical strategies for the prevention, diagnosis, treatment and cure of human diseases, injuries and conditions through human stem cells. Accelerating research with targeted investments This mission is why the MSCRF invests in unique companies like RoosterBio. Founded in 2013, RoosterBio provides standardized, scalable stem cell products and biomanufacturing solutions to support regenerative medicine, cell therapy and tissue engineering. RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to boost the implementation of scalable advanced therapies. 'We're helping to de-risk the industry because people can now test out their product concepts at a fraction of the cost, in a fraction of the time,' said Jon Rowley, founder and chief product officer of the company. Over the past decade, the MSCRF has invested $1.89 million in RoosterBio through four grants. This investment has resulted in a near 40x return to the state, as RoosterBio has brought in $25 million in venture capital funding and more than $50 million in revenues over that span. While the MSCRF's impact within the state is evident, one underrated benefit of the program is its ability to boost Maryland's external connections. Last year, the MSCRF opened its doors to companies outside of Maryland, as long as the research conducted was done within the state. 'The MSCRF has been extremely successful in bringing visibility to the great research and opportunities we have here in the state,' said LeMaile-Stovall. 'We must learn how to fail fast, pivot faster and relaunch the next version even faster. That's part of the scientific process, to try, experiment, learn and retry again. This is all part of both the innovation and entrepreneurial process.' This eagerness to try different things will be critical as we continue to explore stem cell product development. 'We're only just starting to scratch the surface on knowing how to get these products developed that they work after they've been manufactured at scale and then onto the market,' Rowley said.
Technical.ly
29-01-2025
- Technical.ly
As demand for AI infrastructure surges, Johns Hopkins experts warn of deregulation risk
Donald Trump made artificial intelligence one of his biggest key priorities during his presidency's first days. He signed his own AI executive order after axing the previous administration's and is taking part in the major private AI infrastructure project Stargate. It's early, and plenty of unknowns about the future of regulation still remain. But experts anticipate that many of Trump's decisions so far will have major downstream effects on how we use AI. For example, the recent blows to diversity, equity and inclusion practices can ripple into how healthcare systems implement AI and harm patients. Plus, power needs from AI infrastructure will continue to rise, then translate to higher electric bills for consumers. Scholars and researchers from Johns Hopkins University shared these and other predictions for AI under Trump during a recent media briefing. Here are some of their key takeaways. Demands from data centers will continue to increase As AI systems become more embedded in day-to-day operations, so does the need for supplies to fuel the demand increase. Physical infrastructure like data centers is a major part of this need. The massive structures will continue to pop up across the US, per Tinglong Dai, a business analytics professor at Johns Hopkins. There's already a massive concentration of data centers in Loudoun County, Virginia's self-named Data Center Alley, and projects like Stargate entail data center development in places like Texas. 'When we talk about the data centers, we are really talking about billions of dollars.' Tinglong Dai, JHU Business analytics professor All that points to a greater need for electricity: Data centers consume 2% of power generated in the US, and that number's is expected to triple by 2030. Data centers also need water to cool their systems, Dai explained, even though some companies claim to use little to no water. This trend arose long before Trump was elected for a second term, and Dai said both the current Trump and Biden administrations shared priorities in the push for energy to power data centers. The trend also boasts a lot of funding. 'When we talk about the data centers, we are really talking about billions of dollars [of] money involved,' Dai told reporters. 'It's extremely capital intensive.' Dai also highlighted sustainability concerns like the reliance on fossil fuels for power and rising electricity prices for the average consumer. Anti-DEI stance puts health equity at risk As researchers pursue clinical trials and tests to implement AI in health systems, the administration's aggressive step away from DEI could impact patient care, per Suchi Saria, the director of Johns Hopkins' AI and Healthcare Lab. 'Given this administration's focus on banning the DEI-related efforts,' Saria told reporters, 'how does this play out in the context of healthcare, where there were very concrete initiatives that were put in place to improve health equity?' This has been an issue for the past few years. Major corporations like UnitedHealthcare implemented AI tools that then hurt patients, she explained. There's a need to document and streamline the consequences if these entities implement AI poorly, as well as define how liability works, she said. 'The presence of best practices to accelerate AI adoption creates a semblance of sanity.' Suchi Saria, JHU AI & HealthCare Lab director AI adoption in healthcare isn't going away, and there are many positive use cases: Saria cited the example of using the tech to alleviate workforce demands, which also drives more AI adoption. Looking forward, the government needs to be united in how it regulates and guides AI use and adoption, she said. 'Multiple conflicting guidelines make it difficult,' Saria said. 'There is a need for some kind of best practice. Because I do think the presence of best practices to accelerate AI adoption creates a semblance of sanity.' There's very little AI regulation. Building trust is key to its success The Biden administration's first AI executive order set up systems to create guidelines and research when it comes to the text, but very few regulations exist on the books. But regulatory concerns won't go away, said Gillian Hadfield, a computer science professor with an appointment at Johns Hopkins' School of Government and Policy. It's necessary to build trust with people. That's the case in other industries, like restaurants and school systems, she said. 'We're all willing to continue to participate in this incredibly complex society we live in where somebody else grows our food, and somebody else sticks needles in us,' Hadfield said. 'We are willing to do it on a mass scale because we believe that they have been vetted.' That expectation is missing in AI right now. There isn't a check on the system or testing in place. Plus, despite Trump's own belief that prior federal oversight 'hampered the private sector's ability to innovate in AI,' Hadfield explained that companies don't have to compromise innovation for regulation. She's seen many firms look for regulatory structures so they can better manage risks. 'I think effective regulation of AI,' Hadfield said, 'provides us with confidence.'
